ALK/HDAC-IN-1
ALK/HDAC-IN-1 is a dual inhibitor for ALK and HDAC6, with IC50s of 16 nM and 1.03 μM, respectively. ALK/HDAC-IN-1 exhibits antitumor activity.
For research use only. We do not sell to patients.
- Formula: C27H31N5O4
- Molecular Weight:489.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
HDAC6 1.03 μM (IC50) |
HDAC8 1.69 μM (IC50) |
HDAC1 10.8 μM (IC50) |
HDAC11 16.6 μM (IC50) |
In Vitro
ALK/HDAC-IN-1 inihibits proliferations of cancer cells A549, HepG2, MCF7, U87MG and H2228, with IC50s of 0.33, 0.59, 0.55, 0.62 and 0.44 μM, respectively[1].
ALK/HDAC-IN-1 inihibits CYP450 enzymes CYP2C9 with IC50 of 2.65 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549, HepG2, MCF7, U87MG and H2228
-
Concentration:
-
Incubation Time:48 h
-
Result:Inhibited proliferations with sub-micromolar level IC50 values.
-
Cell Line:H2228
-
Concentration:2 μM
-
Incubation Time:6 h
-
Result:Ptomoted acetylation of α-tubulin and histone H3.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A549 xenografted BALB/c mice[1]
-
Dosage:0-20 mg/kg
-
Administration:i.p., once daily for 21 days
-
Result:Decrease tumor growth with TGIs of 68% and 85%, with dose of 10 and 20 mg/kg, respectively.
Chemical Information
-
Molecular Weight 489.57
-
Formula C27H31N5O4
-
SMILES
O=C(/N=C1N([C@@H]2CC[C@H](C(NC(C)C)=O)CC2)C3=CC=C(/C=C/C(NO)=O)C=C3N/1)C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ALK/HDAC-IN-1 Related Classifications
HY-161350 Related Classifications
Powered by Bioz